Intellia Therapeutics, Inc

We provide actionable Strategic Insights with the highest quality operations with 24/7 Global Support

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.

Acceleron Pharma, Inc is a biopharmaceutical company based in Cambridge, MA that utilizes cutting-edge science to develop innovative medicines and vaccines to save and improve lives worldwide. With a focus on scientific innovation, they tackle some of the world's greatest health threats, including oncology, infectious diseases, and cardio-metabolic disorders. Through their research and development efforts, Acceleron Pharma follows the science to make a significant impact in the field of healthcare. They conduct clinical trials to identify potential new treatments and collaborate with experts to answer important scientific questions. Committed to sustainability, they operate responsibly to ensure a safe and healthy future for communities globally.Generated from the website